Published 24 days ago

Did you say 486%? Why one company thinks such a price hike for its drug is justified

Summary by STAT

Harrow argues its eye treatment, which has been out of stock for years, is underpriced and requires substantial investment in manufacturing.

0 Articles

All

Left

Center

Right

Harrow argues its eye treatment, which has been out of stock for years, is underpriced and requires substantial investment in manufacturing.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated24 days agoBias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)